Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Ixabepilone Pregnancy and Breastfeeding Warnings

Ixabepilone is also known as: Ixempra

Medically reviewed on August 6, 2018

Ixabepilone Pregnancy Warnings

Ixabepilone has been assigned to pregnancy category D by the FDA. Animal studies have revealed evidence of embryotoxicity and fetotoxicity in rabbits and rats. There are no controlled data in human pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy. Ixabepilone should only be given during pregnancy when there are no alternatives and benefit outweighs risk.

Animal studies have resulted in reduced ossification of caudal vertebrae, sternebrae and metacarpals, a decrease in implantations and live fetuses, and increased resorptions and embryo-fetal deaths.

See references

Ixabepilone Breastfeeding Warnings

There are no data on the excretion of ixabepilone into human milk. The manufacturer recommends that due to the potential for serious adverse effects in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.

References for breastfeeding information

  1. "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide